The studies to be reviewed include late stage design of vaccines, evaluation of immune responses to vaccines, adjuvants and vaccine delivery systems and tests of their safety and efficacy in in vitro and in vivo systems. Areas of interest are focused on processes of vaccine research and development, applied immunology and translational research, and preclinical-clinical vaccine development.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Immune response characterization relevant to vaccines: antibody neutralization, innate and adaptive immunity; B and T cell response, dendritic cell function, mast cell and macrophage function; mucosal immunity; immune response modifiers including cytokines and chemokines, Fc receptors, Toll-like receptors; antigen presentation and its role in generating effective protective immunity.
- Vaccines against pathogens of clinical or veterinary interest: bacteria; viruses (except HIV); parasites and fungi; bacterial toxins; pathogenic agents that have biodefense implications
- Vaccine development: adjuvant development and optimization; protein, nucleic acid or mixed conjugates; immunomodulators; synthetics, including nanoparticles or vector-based vaccine platforms; DNA vaccines; mRNA vaccines; peptide and protein vaccines; subunit vaccines; inactivated whole organism vaccines; live-attenuated vaccines; plant-based vaccines; optimization of vaccine delivery using vectors, plasmids and virus-like particles; all relevant vaccine delivery routes; vaccine formulations.
- Animal models and human subjects related studies relevant to vaccine testing: small and large animal models; studies using human samples; human pre-clinical and clinical assessment of protective immune responses; evaluation of immunogenicity; protection against pathogen challenge; vaccine efficacy and safety; improvement of the safety of existing vaccines.
Shared Interests and Overlaps
There are shared interests with Immunity and Host Defense Study Section (IHD) in immune response to microbes. Applications focused on basic immunological studies such as mechanistic studies of the innate, systemic and mucosal immune responses to microbial organisms with minor vaccine development topics may be reviewed by IHD. Applications focused on immune response to vaccines with major vaccine development topics (process, translational research) may be reviewed by VMD.
There are shared interests with Innate Immunity and Inflammation (III). Applications focused on basic innate and adaptive immunity and inflammation, including studies of soluble and cellular mediators of these processes, such as lipid based adjuvants with minor vaccine development topics may be reviewed by III. Applications focused on evaluation of adjuvants in vaccine formulation or innate and adaptive immunity induced by vaccines may be reviewed by VMD.
There are shared interests with Cellular and Molecular Immunology -A/B [Cellular and Molecular Immunology A (CMIA) /Cellular and Molecular Immunology B (CMIB)]. Applications focused on basic studies of T/B cell differentiation and function, epitope identification and structure, molecular recognition, antibody engineering, affinity/avidity studies, and protein and lipid biochemistry may be reviewed by CMIA/CMIB. Applications involving testing of immune responses to vaccines in vitro or in vivo may be reviewed by VMD.
There are shared interests with Virology A & B Study Sections (VIRA & VIRB) in host-virus interaction. Applications involving early stage vaccine research including design and testing of viral vaccine candidates or study of viral pathogenesis at molecular levels may be reviewed by VIRA & VIRB. Applications where vaccine development is in its late stage such as testing of vaccine efficacy against viral pathogens maybe reviewed by VMD.
There are shared interests with the Host Interactions with Bacterial Pathogens Study Section (HIBP) and Pathogenic Eukaryotes Study Section (PTHE). Applications involving early stage vaccine research including design and testing of vaccine candidates derived from bacterial or eukaryotic pathogens or study of their pathogenesis at molecular levels may be reviewed by HIBP or PTHE. Applications where vaccine development is in its late stage such as testing of vaccine efficacy against bacterial or eukaryotic pathogens may be reviewed by VMD.
There are shared interests with Nanotechnology Study Section (NANO) in developing novel nano-compounds. Applications involving the design, synthesis, and development of nanoparticles with minor vaccine related topics may be reviewed by NANO. Applications with focus on using synthesized nanoparticles for vaccine delivery and testing its vaccine efficacy may be reviewed by VMD.